Patricia Izurieta1, Woo Joo Kim2, Seong-Heon Wie3, Jacob Lee4, Jin-Soo Lee5, Mamadou Dramé6, David W Vaughn6, Anne Schuind6. 1. GSK Vaccines, Wavre, Belgium. Electronic address: patricia.s.izurieta@gsk.com. 2. Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea. 3. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, South Korea. 4. Division of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, South Korea. 5. Division of Infectious Diseases, Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea. 6. GSK Vaccines, King of Prussia, PA, USA.
Abstract
BACKGROUND: AS03-adjuvanted H5N1 pandemic influenza vaccines have been assessed in an extensive clinical development program conducted in North America, Europe, and Asia including children from 6 months of age, adults, and elderly adults. We evaluated AS03-H5N1 in Korean adults 18 through 60 years of age. METHODS: This Phase IV, randomized, study was conducted to assess the immunogenicity, reactogenicity, and safety of two doses (3.75μg of hemagglutinin antigen) of A/Indonesia/5/2005 (H5N1) adjuvanted with AS03 given 21 days apart in Korean adults. Antibody responses were assessed using hemagglutination-inhibition (HI) assays against the vaccine strain and a vaccine-heterologous strain (A/Vietnam/1194/2004) 21 days after the second dose. A control group (safety) received a licensed seasonal inactivated trivalent influenza vaccine (TIV). Reactogenicity was assessed for 7 days after each vaccination, and unsolicited adverse events were assessed for 182 days following vaccination in both study groups (NCT01730378). RESULTS:AS03-H5N1 was immunogenic and elicited robust HI antibody responses with seroconversion rates of 100% for the vaccine strain and 69.1% for the heterologous strain (N=81). HI antibody responses fulfilled the European licensure criteria for immunogenicity (primary endpoint). The incidence of local and systemic solicited adverse events (reactogenicity) was higher with AS03-H5N1 than TIV. There was no apparent difference in the rate of unsolicited adverse events in the AS03-H5N1 and TIV groups. CONCLUSION: The results indicate that AS03-H5N1 vaccine is immunogenic with reactogenicity and safety findings that are consistent with the established profile of AS03-H5N1 vaccine.
RCT Entities:
BACKGROUND:AS03-adjuvanted H5N1 pandemic influenza vaccines have been assessed in an extensive clinical development program conducted in North America, Europe, and Asia including children from 6 months of age, adults, and elderly adults. We evaluated AS03-H5N1 in Korean adults 18 through 60 years of age. METHODS: This Phase IV, randomized, study was conducted to assess the immunogenicity, reactogenicity, and safety of two doses (3.75μg of hemagglutinin antigen) of A/Indonesia/5/2005 (H5N1) adjuvanted with AS03 given 21 days apart in Korean adults. Antibody responses were assessed using hemagglutination-inhibition (HI) assays against the vaccine strain and a vaccine-heterologous strain (A/Vietnam/1194/2004) 21 days after the second dose. A control group (safety) received a licensed seasonal inactivated trivalent influenza vaccine (TIV). Reactogenicity was assessed for 7 days after each vaccination, and unsolicited adverse events were assessed for 182 days following vaccination in both study groups (NCT01730378). RESULTS:AS03-H5N1 was immunogenic and elicited robust HI antibody responses with seroconversion rates of 100% for the vaccine strain and 69.1% for the heterologous strain (N=81). HI antibody responses fulfilled the European licensure criteria for immunogenicity (primary endpoint). The incidence of local and systemic solicited adverse events (reactogenicity) was higher with AS03-H5N1 than TIV. There was no apparent difference in the rate of unsolicited adverse events in the AS03-H5N1 and TIV groups. CONCLUSION: The results indicate that AS03-H5N1 vaccine is immunogenic with reactogenicity and safety findings that are consistent with the established profile of AS03-H5N1 vaccine.
Authors: Joon Young Song; Min Joo Choi; Ji Yun Noh; Won Suk Choi; Hee Jin Cheong; Seong-Heon Wie; Jin-Soo Lee; Gyu-Jin Woo; Sang Ho Lee; Woo Joo Kim Journal: Hum Vaccin Immunother Date: 2016-12-20 Impact factor: 3.452
Authors: Wivine Burny; Andrea Callegaro; Viviane Bechtold; Frédéric Clement; Sophie Delhaye; Laurence Fissette; Michel Janssens; Geert Leroux-Roels; Arnaud Marchant; Robert A van den Berg; Nathalie Garçon; Robbert van der Most; Arnaud M Didierlaurent Journal: Front Immunol Date: 2017-08-14 Impact factor: 7.561
Authors: Pekka Ylipalosaari; Tero I Ala-Kokko; Jouko Laurila; Lauri Ahvenjärvi; Hannu Syrjälä Journal: BMC Infect Dis Date: 2017-11-21 Impact factor: 3.090